Interrupting antiretroviral treatment needs particular care

BMJ 2001; 322 doi: https://doi.org/10.1136/bmj.322.7286.616 (Published 10 March 2001) Cite this as: BMJ 2001;322:616
  1. W A C Sewell, specialist registrar,
  2. C Mazhude, specialist registrar,
  3. A Murdin-Geretti, lecturer,
  4. S Jones, senior pharmacist,
  5. P J Easterbrook, professor (philippa.easterbrook@kcl.ac.uk)
  1. Academic Department of HIV/Genitourinary Medicine, Guy's, King's and St Thomas's School of Medicine, Weston Education Centre, London SE5 9RT

    EDITOR—Noble and Kehlet raise an important issue in their editorial about the interruption of drug treatment during the postoperative period.1 We would emphasise the particular problems of drug interruptions in HIV infected patients receiving combination antiretroviral treatment; in these patients the general rule that some drugs are better than none does not apply.

    Efavirenz and nevirapine are both non-nucleoside reverse transcriptase inhibitors with long plasma half …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription